Today Edap Tms SA (EDAP) Given $6.50 Average Target Price by Analysts – DailyQuint

Shares of Edap Tms S.A. (NASDAQ:EDAP) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1 year consensus target price of $6.50 for the company and are expecting that the company will post $0.01 earnings per share for the current quarter, according to Zacks. Zacks has also given Edap Tms an industry rank of 157 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised Edap Tms from a hold rating to a buy rating and set a $3.25 price target for the company in a research report on Tuesday, October 11th.

Edap Tms (NASDAQ:EDAP) traded down 0.6923% on Tuesday, hitting $3.2275. The stock had a trading volume of 6,412 shares. The company has a market cap of $92.72 million, a price-to-earnings ratio of 8.0890 and a beta of 1.29. Edap Tms has a 52-week low of $2.43 and a 52-week high of $4.80. The company has a 50 day moving average price of $3.29 and a 200-day moving average price of $3.04.

An institutional investor recently raised its position in Edap Tms stock. Wells Fargo & Company MN raised its stake in shares of Edap Tms S.A. (NASDAQ:EDAP) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,655 shares of the companys stock after buying an additional 2,000 shares during the period. Wells Fargo & Company MN owned approximately 0.67% of Edap Tms worth $562,000 at the end of the most recent quarter. 9.52% of the stock is currently owned by institutional investors.

Edap Tms Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Go here to read the rest:

Today Edap Tms SA (EDAP) Given $6.50 Average Target Price by Analysts - DailyQuint